LungLifeAI Logo

Early detection

is key

LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.

Our purpose
is simple

Featured News

April 17, 2025

Exclusive License and Distribution Agreement; Operational Update; Further on Proposed Cancellation of Admission to Trading on AIM   

 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has entered into a conditional exclusive license and distribution agreement (the “Agreement”) for the commercial distribution of its LungLB® test (the “LungLB® test”) in the US with Circulogene Theranostics, Inc. a US liquid biopsy diagnostics company (“Circulogene” or the […]
• Read More
February 4, 2025

Operational and Funding Update and Proposed Cancellation from AIM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides the following update.  As set out in the Operational Update on 19 November 2024, the Company had been actively engaged in discussions with several potential strategic partners. These discussions were aimed at identifying a partner that not only shares the Company’s […]
• Read More
1 2 3 37
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down